2024;4(1):e8-e17
There is a broad consensus that GLP-1 receptor agonists have transformed the management of T2D, obesity, and related morbidity and have been associated with reduced progression of renal disease, cardiovascular disease, and mortality in people with metabolic disorders
Search Strategy Five electronic databases, PubMed, Scopus, Web of Science, ClinicalTrials.gov, and PsycNet, were searched on June 10, 2023, using the search terms (semaglutide OR GLP-1 analog OR GLP-1 agonist) AND (psychiat* OR depress* OR anxiety OR psycho* OR schizo* OR bipolar OR substance OR ADHD OR attention OR dementia OR autism OR alcohol use disorder OR AUD OR Alzheimers disease) AND (treatment). No restrictions on language, country, publication year, or patient age, gender, or ethnicity were applied
Purification and characterization of urinary metabolites of alpha-tocopherol
The flushing volume of the filter membrane should be optimized according to the characteristics of the sample
Figure 4 The involvement of PI hydrolysis/Ca 2+ and cAMP/PKA pathways in OA-mediated GLP-1 and PYY release was examined using selective inhibitors